Kadcyla has no negative impact upon the future of NeuVax. To the contrary, considering Kadcyla helps to (somewhat) extend life - barter for a few more months of life - gives tremendous credence to the argument and to COMBINING NeuVax with Herceptin in seeking to REDUCE RECURRENCE. Review portions of the Phase II NeuVax data wherein this exact combo reduced recurrences to an astonishing 0%!!!! No Recurrence or Delayed Recurrences translates into longer life and better quality of life! Kadcyla is among those therapies provided as a last-ditch effort to attempt to extend (albeit for a mere 6 to 8 months) life. If you seek to MEANINGFULLY extend survival, the NeuVax and Herceptin combo certainly offers far more hope and inspiration than does Kadcyla.